Navigation Links
Semafore's SF1126 Exhibits Antitumor and Antiangiogenic Activity
Date:1/9/2008

INDIANAPOLIS, Jan. 9 /PRNewswire/ -- Semafore Pharmaceuticals Inc. today announced that a paper published in Cancer Research (2008; Vol. 68, Issue 1: 206-215) reports that SF1126, the company's lead product candidate, exhibits antitumor and antiangiogenic activity.

The paper, entitled "A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity," is based on preclinical studies conducted by Semafore and collaborators at Children's Healthcare of Atlanta, Emory University School of Medicine, and M.D. Anderson Cancer Center. Phosphoinositide 3-kinase (PI3K) is a powerful pathway and an emerging cancer target for inhibition. In the studies reported, SF1126 showed favorable pharmacokinetics and pharmacodynamic effects as indicated by inhibition of downstream signaling elements both in vitro and in vivo. In addition, SF1126 displayed potent antitumor and antiangiogenic activity in vivo, in mouse models, against a variety of human cancer cell types, including prostate, breast, neuroblastoma, and glioblastoma.

SF1126 differs from other known PI3K inhibitors in that it has a homing feature designed to localize more drug in the tumor compartment. Based on the studies reported in the paper, SF1126 also significantly enhanced the activity of docetaxel in a combination regiment in a prostate cancer model.

"The data further support our belief that SF1126 is a viable pan PI3K inhibitor as we continue Phase I clinical trials," said Ed Jacobs, Semafore's president and chief executive officer. "SF1126 continues to support the paradigm shift in cancer treatment that will see the application of highly targeted therapeutic drugs that inhibit the powerful PI3K pathway."

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major fact
'/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
2. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
3. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
4. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
5. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
6. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
9. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
10. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
11. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
(Date:1/14/2014)... 2014 The Brandeis Medical Center, led by Dr. Emmanuel ... and affordable laser tattoo removal experience with the advanced Astanza Duality ... providing high quality cosmetic services with cutting edge medical technology and ... Southern California has seen a dramatic increase in the ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Application Enables Collaboration by Connecting SciVerse ... , Elsevier , a world-leading provider of scientific, technical ... of an expert identification and discovery application that connects ... and research synthesis, with the DIRECT2Experts online ...
... 14, 2012  Organovo Holdings, Inc. (OTCQB: ONVO) ("Organovo") ... on February 8, 2012, with Organovo, Inc. (the ... three-dimensional bioprinting technology for research and medical applications.  ... placement consisting of approximately 6.5 million units of ...
Cached Medicine Technology:Elsevier Introduces Expert Discovery Application for SciVerse Hub 2Elsevier Introduces Expert Discovery Application for SciVerse Hub 3Elsevier Introduces Expert Discovery Application for SciVerse Hub 4Organovo Announces $6.5 Million Private Placement to Advance 3D Bioprinting for Medical Applications 2Organovo Announces $6.5 Million Private Placement to Advance 3D Bioprinting for Medical Applications 3
(Date:4/18/2014)... A new medical-testing device is being prepped to ... could improve diagnosis of certain diseases in remote ... a series of investigations aboard the International Space ... uses the space-tested concept of capillary flow to ... , David Kelso, Ph.D., a researcher at Northwestern ...
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... French . ... regenerative medicine. A team led by Ludwik Leibler from ... and Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle ... that the principle of adhesion by aqueous solutions of ... organs and tissues. This easy-to-use gluing method has been ...
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... , MONDAY, March 14 (HealthDay News) -- Women may ... a diet rich in two types of B vitamins, a ... and riboflavin (B2) in their food significantly reduced their risk ... fortified cereals, whole grains, beans and nuts, and researchers said ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, March ... that is, a pediatrician or nurse they see regularly who offers ... dental needs met, new research finds. Yet it,s the sickest ... and require the most care -- who are less likely to ...
... the globe are making headway in fighting communicable diseases ... research from the Frederick S. Pardee Center for International ... School of International Studies. The center ... volumes that focus on human progress in which researchers ...
... human studies of an oral drug regimen to prevent HIV ... in HIV incidence, but a number of issues require additional ... a large scale, according to an article in AIDS ... Mary Ann Liebert, Inc. ( www.liebertpub.com ). The article is ...
... Research and Education recently received a five year, $3.7 ... and Agriculture to fund a project aimed at preventing ... to teach mothers simple yet authoritative strategies to promote ... The grant was awarded to Jenifer Orlet Fisher, associate ...
... ,Scientists at the National Institute of Allergy and Infectious ... have shown how the O157:H7 strain of Escherichia ... host immune response. The bacterium secretes a protein called ... alter specific immune responses. This process not only helps ...
Cached Medicine News:Health News:Diets Rich in Vitamin B May Help Prevent PMS, Study Finds 2Health News:'Medical Homes' Help Kids Get Comprehensive Care 2Health News:'Medical Homes' Help Kids Get Comprehensive Care 3Health News:DU researchers find that headway being made fighting communicable diseases globally 2Health News:DU researchers find that headway being made fighting communicable diseases globally 3Health News:Early success of anti-HIV preventive oral drug regimen is promising, but questions remain 2Health News:Temple receives $3.7 million to study parenting styles' effect on childhood obesity 2
Baby Weitlaner retractor, blunt, 4"....
Bruns (Volkmann) bone curette, with Novotex plastic handle (autoclavable in autoclave up to 143C by 3 bar), 9, oval....
15" overall length, 5" handle....
15" overall length, 9" handle....
Medicine Products: